NextCure Inc. (NXTC) Prices 4.077M Share Common Offering at $36.75/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/1/2026
- Wall Street ends higher as Amazon soothes AI jitters
- Amazon shares rally as cloud growth surges and spending outlook climbs
- Apple shares sink on disappointing September quarter sales outlook
- Novo Nordisk stock tumbles 10% as key trial misses goal
- AI wizkid Leopold Aschenbrenner forced to sell entire portfolio after rout
- SCYNEXIS (SCYX) Move Attributed to Morning Note from Brookline
- AbbVie (ABBV) Misses Q2 EPS by 6c, Beats on Revenue; Offers FY26 EPS Guidance
- Short sellers pile into SpaceX ahead of earnings, lockup expiration
- Wall Street ends higher as Amazon soothes AI jitters
- Novo Nordisk's ziltivekimab fails to reduce heart risk in ZEUS trial
- After-Hours Stock Movers: AAPL, AMZN, COIN, RBLX, RDDT, AXTI, FND, WU, GDDY
- After-Hours Stock Movers: META, MSFT, CMG, SBUX, CVNA, LRCX, FTNT, QCOM, TDOC
- After-Hours Stock Movers: F, BE, STX, WDC, KLAC, SWKS, NXPI, CSGP, ENPH
- After-Hours Stock Movers: FFIV, CDNS, APLD, RMBS, ESI, SANM
- After-Hours Stock Movers: INTC, AMD, ARM, MXL, EW, DECK
NextCure Announces Pricing of Public Offering of Common Stock
November 14, 2019 10:11 PM ESTBELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 611,578 shares of its common stock at the public offering price less the underwriting discounts and commissions. All of the common stock to... More
NextCure Announces Pricing of Public Offering of Common Stock
November 14, 2019 10:09 PM ESTBELTSVILLE, Md., Nov. 14, 2019 (GLOBE NEWSWIRE) -- NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced the pricing of its public offering of 4,077,192 shares of its common stock at a public offering price of $36.75 per share. NextCure also granted the underwriters a 30-day option to purchase up to an additional 611,578 shares of its common stock at the public offering price less the underwriting discounts and commissions. All of the common stock to be sold in the offering are being... More
